NeuroEPO Important Update
July 24, 2026
Welcome to the new format of Greg’s Alzheimer’s Research Report.
Each report now begins with a brief summary, allowing you to instantly assess its relevance, grasp the core insights, and decide if the full piece warrants a deeper dive.
On average, I spend three hours producing each report. This rigorous process involves scouring scientific journals for critical topics, tracking clinical trial updates, and analyzing extensive background data to bring you accurate, actionable information.
Effective July 14, 2026, our format will change. The brief report summaries will remain free to all readers, while access to the complete, in-depth reports will transition to a paid subscription model.
This subscription directly supports the time and research required to sustain this platform. We offer three ways to stay informed:
Monthly Subscription: $10 per month
Annual Subscription: $100 per year (Save $20 annually)
Founder’s Circle: $250 per year (Includes an exclusive monthly video conference to discuss emerging Alzheimer’s treatments in close detail)
SUMMARY:
Interest in NeuroEPO (also called NeuralCIM) is surging among Alzheimer’s patients and their loved ones in the United States. In this report, I provide the reasons why an American pharmaceutical company is not licensing NeuroEPO or manufacturing a similar drug. Most importantly, this report gives you all the information needed to safely travel to Cuba to obtain this very promising drug.
Please consider subscribing to read this report. All proceeds support my Alzheimer’s treatment.
Thank you.
